Business Wire

IDEMIA

13.7.2021 12:48:11 CEST | Business Wire | Press release

Share
IDEMIA Announces a Global Partnership With Bosch Building Technologies to Tap the $1bn Biometric Access Control Market

IDEMIA, the leader of Augmented Identity announced today a global partnership with Bosch Building Technologies, a global leader in the security market, to tap the fast-growing biometric access control market. According to market analysts1 , this market at $1bn in 2021, will grow to $1.4 by 2024 , twice the growth of traditional access control systems.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005582/en/

This booming market comes from the fact that a growing number of companies understand that for their security, they cannot rely anymore only on simple ID badges, that can be cloned (for older technologies still used by 44% of companies2 ) or simply stolen. The consequence is that it is never possible to know with certainty who is entering the premises. Biometrics , based on personal, physiological, unforgeable characteristics, provide the highest degree of certainty that the person passing the door is a genuine authorized employee. Bosch Building Technologies offers a software solution that manages different Bosch security subsystems like access control, video surveillance, fire alarm, public address and intrusion systems on one single platform, the Bosch Building Integration System (BIS) . This robust and reliable security and life safety system is proven by over 3000 installations integrating 10 million detectors worldwide.

In order to add a biometric layer to BIS, Bosch has selected IDEMIA’s terminals: IDEMIA is the market leader of biometrics for access control with more than 25 year’s experience in that domain, and hundreds of thousands of terminals successfully deployed for a great variety of industries, throughout the world.

Bosch will offer IDEMIA’s flagship contactless biometric terminals:

  • MorphoWaveTM , the only terminal in the world capable of scanning and verifying 4 fingerprints in less than 1 second through a quick, simple and fully touchless wave movement of the hand,
  • VisionPass the most advanced facial recognition terminal combining 2D, 3D and infrared cameras with IDEMIA’s leading facial algorithms.

Both terminals combine high biometric accuracy, speed and convenience with a fully touchless user experience. They operate efficiently with sanitary masks and are therefore well adapted for Covid-prevention policies. IDEMIA terminals are already integrated with the BIS platform and with most gates and turnstile vendors. This will greatly facilitate deployments in Bosch specific markets with a focus on commercial buildings, industrial and logistics sites, government premises and airports/seaports.

Bosch stands for quality and reliability. We want to offer innovative and fascinating solutions, as our slogan 'invented for life' states. When our customers are going to deploy biometric terminals for their security, they will be installed for years so we want to offer them the best option”, explains Gregor Schlechtriem, Senior Vice President Bosch Building Technologies Business Unit Access & Intrusion . “Idemia is therefore for us the right partner because of their technology expertise and field-proven quality and performances”, Schlechtriem continues.

“We are delighted to start this global partnership with Bosch”, commented Yves Portalier, EVP Biometric Devices and Automotive at IDEMIA . “The combination of our biometric devices with the BIS platform will be a strong offering for companies looking for a high level of security and user convenience”.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

1 In particular leading market analysis firm OMDIA
2 According to a ASIS International 2019 survey

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye